According to the latest study published in the “Drugs” journal, intravenous golimumab significantly improve clinical outcomes in RA patients switching from infliximab.

Direct shifting from one anti-TNF to other anti-TNF may help to reduce disease expansion. Therefore, Vance J. Bray and colleagues conducted an analysis to assess Golimumab efficacy and utilization through real-world RA population who directly shifted from Infliximab to intravenous Golimumab.

A total of five US-based rheumatology practices were utilized to extract patient charts. Overall, 113 patient charts were assessed for treatment characteristics, intravenous Golimumab and Infliximab utilization data, patient demographics along with Routine Assessment of Patient Index Data (RAPID3) scores, Clinical Disease Activity Index (CDAI), Physician Global Assessment (PhGA) and Patient Global Assessment (PtGA). A comparison of pre- and post IV Golimumab induction was done to evaluate its efficacy.

A considerable decline was seen in disease activity; mean PhGA and CDAI scores after shifting to IV Golimumab whereas PtGA and RAPID3 scores exhibited minimal changes. During the post IV Golimumab period, a significant portion of the population showed a remarkable reduction in disease activity (p < 0.05).